Page last updated: 2024-09-05

butyrylcarnitine and hippuric acid

butyrylcarnitine has been researched along with hippuric acid in 2 studies

Compound Research Comparison

Studies
(butyrylcarnitine)
Trials
(butyrylcarnitine)
Recent Studies (post-2010)
(butyrylcarnitine)
Studies
(hippuric acid)
Trials
(hippuric acid)
Recent Studies (post-2010) (hippuric acid)
2921390939218

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Beaumont, M; Cassidy, A; Glastonbury, CA; Jackson, MA; Jennings, A; MacGregor, A; Martin, TC; Menni, C; Mohney, RP; Pallister, T; Small, KS; Spector, TD; Steves, CJ; Valdes, AM1
Akrami, M; Chamoto, K; Fagarasan, S; Hatae, R; Hirai, T; Honjo, T; Kawaguchi, S; Kim, YH; Masuda, I; Matsuda, F; Okuno, Y; Ozasa, H; Sakamori, Y; Sonomura, K; Taneishi, K; Yoshida, H1

Other Studies

2 other study(ies) available for butyrylcarnitine and hippuric acid

ArticleYear
Untangling the relationship between diet and visceral fat mass through blood metabolomics and gut microbiome profiling.
    International journal of obesity (2005), 2017, Volume: 41, Issue:7

    Topics: Adult; Bilirubin; Biomarkers; Blood; Butyrates; Carnitine; Diet; Eating; Feces; Female; Fruit; Gastrointestinal Microbiome; Globins; Hippurates; Homeostasis; Humans; Indoles; Intra-Abdominal Fat; Male; Metabolomics; Nerve Tissue Proteins; Neuroglobin; Nutritional Status; Oxidation-Reduction; Red Meat; United Kingdom; Valerates; Vegetables; Yogurt

2017
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.
    JCI insight, 2020, 01-30, Volume: 5, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carnitine; Drug Therapy, Combination; Energy Metabolism; Female; Glutathione Disulfide; Hippurates; Humans; Immunotherapy; Lung Neoplasms; Male; Microbiota; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Prospective Studies

2020